Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

ll be set based on evaluation from the first stage pharmacokinetic study using the new formulation. The second stage will evaluate the safety and tolerability of LX6171 oral suspension in subjects exhibiting AAMI and will measure the cognitive effects of LX6171 in these subjects using the Cognitive Drug Research battery, along with other psychometric instruments. The study is being conducted in Europe, with initial results expected by the end of 2008.

About LX6171

LX6171 is an orally-bioavailable small molecule developed by Lexicon scientists to inhibit a membrane protein expressed exclusively in the central nervous system and found at synaptic vesicles and presynaptic membranes of glutamatergic neurons. The protein targeted by LX6171 was identified through Lexicon's large-scale gene knockout program, the Genome5000(TM). Knockout mice lacking this protein showed improved learning and memory compared with controls. In preclinical studies, administration of LX6171 resulted in improved performance in tests of learning and memory in mice. In Phase 1 clinical trials, LX6171 was generally well tolerated at all dose levels and showed good systemic exposure.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bris
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... -- The American Association for Homecare (AAHomecare), along with a ... announced today the filing of a lawsuit in ... asking that the scheduled July 1 expansion of the Medicare ... stopped because of serious licensing irregularities. The lawsuit ... Secretary Kathleen Sebelius as the defendant. HHS oversees ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... Agent Ever to Demonstrate Significant Survival Benefit ... /PRNewswire-FirstCall/ -- Bayer,HealthCare Pharmaceuticals Inc. and Onyx ... significantly,extended overall survival in patients with hepatocellular ... taking placebo by 44%,(HR=0.69; p-value=0.0006). Results were ...
... WIRE)--Jun 4, 2007 - Researchers at,Molecular Insight ... on MIP-1072, a radiolabeled, small molecule,molecular imaging ... prostate cancer at the 54th annual meeting ... Washington, D.C. MIP-1072 is,one of two development ...
Cached Medicine Technology:Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4
(Date:6/19/2013)... June 19, 2013 Today, Zane Benefits, ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... Benefits’ website, as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:6/19/2013)... June 19, 2013 The Journal of ... with today’s computer software, it creates questions of ethics. ... misconduct. As an already published case shows, scientific publications ... , The Journal of Parasitology features a ... in a 2004 article published in the Journal of ...
(Date:6/19/2013)... 2013) The results of three important studies have ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... continuous "machine learning" using artificial neural networks (ANNs) may ... advanced brain cancers. Another study in the June ...
(Date:6/19/2013)... (June 19, 2013) In early April, senior leaders ... in Hartford, Connecticut, to discuss one question: how can ... , The preliminary results of this discussion ... Shooter Events: The Hartford Consensus ," a concept paper ... Journal of Trauma and Acute Care Surgery ...
(Date:6/19/2013)... system for repairing damage to the genetic material DNA ... may seem, those compounds are sparking optimism as potential ... mutation in BRCA, a gene that made headlines when ... compounds, termed PARP inhibitors, are the topic of the ... & Engineering News . C&EN is the weekly news ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... CA (June 18, 2010) Leading academic and professional ... online resource that will put the spotlight on research ... http://www.sagepub.com/sageinsight ) links to highly topical articles from across ... SAGE Journals Online. Drawn from both new and archive ...
... ... Pharmaceutical Business , ... York, NY (PRWEB) June 18, 2010 -- LaVoie Group, a leader in life sciences and ... Mr. Pilato will be based in New York, NY and will lead one of ...
... ... issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, twins exposed to ... ... LLP has today issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, ...
... 2010: Two separate studies have shown that vitamin D ... diseases, with over half of all patients having below the ... bodies. A further study assessing response to vitamin D ... normalise vitamin D levels in rheumatic disease patients. The results ...
... 2010: The effects of Systemic Lupus Erythematosus (SLE) may ... to results of a new study presented today at ... Against Rheumatism in Rome, Italy. In particular, the study ... Southern European subpopulations. Results from a Europe-wide study, ...
... ... Plumbing service and heating and air conditioning options for homeowners in ... have increased with the arrival of Berkey’s Plumbing, Heating and Air ... expanding its service area into Irving, Haltom City, Euless, Pantego, Hurst, ...
Cached Medicine News:Health News:LaVoie Group Adds Carey Pilato As Vice President Based In New York 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 2Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 4
... Independent controls for Digital Thermostat and ... clad steel. , Interiorwhite anodized aluminum ... , Oversized refrigeration (134A). , Temperature ... seal self-closing doors. , Foamed-in-place polyurethane ...
Inquire...
... The K Series CryoStorage System ... of liquid nitrogen stroage from -100C ... of solid-state automatic controls, easy accessibility ... at crogenic termperatures. On the larger ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: